PS-PrEP for Preventing HIV Transmission
(PS-PrEP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two methods to prevent HIV transmission using a preventive treatment known as PrEP (pre-exposure prophylaxis). Researchers aim to determine if a new support method called PS-PrEP is more effective than phone-based support in linking people to care. Participants will join one of two groups to compare these approaches. The trial seeks African American/Black men who have sex with men, are HIV-negative, have never taken PrEP, and live in the Chicago area. As an unphased trial, it offers participants the chance to contribute to innovative strategies in HIV prevention.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that pre-exposure prophylaxis (PrEP) is a well-tolerated method for preventing HIV. Studies have found PrEP to be effective and safe for many individuals. For instance, one study confirmed that PrEP is generally safe for HIV prevention. Side effects may occur but are usually mild, such as nausea or headaches, and often resolve over time.
For the PS-PrEP intervention, separate safety data is not available, but since it is based on PrEP, it likely shares the same safety profile. Overall, PrEP has significantly reduced the risk of HIV when used correctly.12345Why are researchers excited about this trial?
Researchers are excited about PS-PrEP because it represents a new approach to preventing HIV transmission. Unlike standard pre-exposure prophylaxis (PrEP) options that primarily involve daily oral pills, PS-PrEP is exploring innovative ways to enhance PrEP effectiveness and adherence. This could be a game-changer, as it may offer a more reliable and user-friendly prevention strategy. By potentially improving how PrEP is used, PS-PrEP could significantly reduce new HIV infections and make a lasting impact on public health.
What evidence suggests that this trial's treatments could be effective for preventing HIV transmission?
Research has shown that pre-exposure prophylaxis (PrEP) effectively prevents HIV. Studies have found that PrEP can reduce the risk of contracting HIV from sex by up to 99% when taken correctly. It also lowers the risk by over 74% for individuals who use injection drugs. In this trial, participants in the PS-PrEP Intervention Group will receive support to facilitate access to and consistent use of PrEP, which is crucial for its effectiveness. By raising awareness and connecting more people to PrEP care, this program aims to maximize its protective benefits. Meanwhile, the PrEPLine Control Group will receive standard PrEP care. Overall, PrEP is a powerful tool in reducing HIV transmission when used as recommended.15678
Are You a Good Fit for This Trial?
This trial is for English-speaking, African American/Black identified MSM aged 18-35 who live in the Chicago area more than half the year. Participants must own a personal cell phone, be HIV negative with completed counseling, and eligible for PrEP treatments according to guidelines but haven't taken PrEP in the last year.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete baseline assessments including surveys on demographics, substance use, mental health, and stigma
Randomization and Initial Intervention
Participants are randomized into intervention or control groups and begin initial intervention sessions
Intervention Follow-up
Intervention group receives follow-up sessions to promote PrEP linkage and retention
3 Month Assessment
Both intervention and control groups complete a survey to track changes over time
6 Month Follow-up
Intervention group receives a mini-booster session to assess and address barriers to PrEP adherence
12 Month Assessment
Final survey for both groups to evaluate long-term outcomes and linkage to care
What Are the Treatments Tested in This Trial?
Interventions
- PrEPLine Control Group
- PS-PrEP Intervention Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor